Article Text

Download PDFPDF

Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’
  1. Ben Mulhearn1,2
  1. 1Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
  2. 2Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
  1. Correspondence to Dr Ben Mulhearn, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust, Bath BA1 3NG, UK; ben.mulhearn{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

I read with great interest the recent work from the COVID-19 European League Against Rheumatism registry authored by Strangfeld et al and the COVID-19 Global Rheumatology Alliance1 describing the risk factors for COVID-19 mortality in patients with rheumatic diseases.

It should perhaps not be surprising that high disease activity in rheumatic diseases is associated with mortality from COVID-19. In rheumatoid arthritis, high disease activity has been shown to be an independent risk factor for severe infection, with a 30% increase in relative risk for every 0.5-unit increase in the 28-joint Disease Activity Score (DAS28).2 The same authors found no association between either biologic or glucocorticoid use and severe infections. The linear relationship between serious infection risk and disease activity has also previously been described by Emery et al.3 Reported serious infections are, however, largely bacterial in nature; susceptibility to severe viral infection appears to be less well understood. Infections are also a leading cause of morbidity and mortality in lupus. Flares in lupus disease activity have been shown to be an independent risk factor for susceptibility to infection, including viral infections.4 All being said, it is clear that having a disordered immune system due to uncontrolled autoimmune disease predisposes to infection in general and the same appears to be true for susceptibility to severe COVID-19 infection.

The study by Strangfeld et al1 clearly showed that there is an association between high-dose glucocorticoid use, as defined by a prednisolone dose of 10 mg or above, and COVID-19 mortality. Glucocorticoids are highly effective immunosuppressants and have even been shown to reduce mortality in severe COVID-19 infection by reducing inflammatory burden.5 It is therefore reasonable to assume that they predispose to infection. In rheumatic diseases, it is well known that glucocorticoids increase the risk of bacterial infection, with one study finding a 10-fold increase in infections with doses of prednisolone 10 mg and above.6 However, what is less clear is whether glucocorticoids are an independent risk factor for COVID-19 mortality or if they are in covariance with disease activity. Current rheumatological practice aims to minimise glucocorticoid exposure due to their systemic side effects. High-dose glucocorticoids are therefore reserved for flaring patients with a rheumatic diagnosis who have, by definition, high disease activity. There will, however, be a number of patients taking a maintenance dose of prednisolone greater than 10 mg, but these patients will also likely have more severe or difficult-to-treat autoimmune disease and therefore have more disordered immune systems.

There are very few, if any, medical reasons to receive high-dose glucocorticoids in the absence of an inflammatory process. This makes the process of untangling disease activity, high-dose glucocorticoid use and COVID-19 mortality a tricky one.



  • Twitter @benmoleskin

  • Contributors BM drafted and submitted the entirety of the report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles